Sunday 18 October 2026
Export SRZN’s income statement to Excel — free account
Surrozen, Inc.
SRZN Healthcare Biotechnology
Surrozen, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $3.5 million, down 67.4% from fiscal 2024. In the quarter to June 2026, revenue grew 408.7%, EPS grew 7.84% and free cash flow fell 21.3%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
23.44
1.63
−6.50%
Follow SRZN
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
0.00 | 0.00 | 0.00 | 0.00 |
P/S ratio |
30.65 | 48.61 | 42.56 | 26.29 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(12.22) | (29.08) | (25.53) | (40.82) | |
P/B ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
Price to Tangible BV |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Sales |
8.09 | 22.94 | 28.29 | 17.43 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(1.39) | (2.64) | (6.34) | (5.77) | |
EV/FCF |
(1.39) | (2.63) | (6.30) | (5.73) | |
Quick Ratio |
12.85 | 9.01 | 11.70 | 11.88 | |
Current Ratio |
13.15 | 9.22 | 11.91 | 12.14 | |
Net Debt/EBITDA |
7.51 | 7.09 | 10.29 | 9.89 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.05 | 0.05 | 0.06 | 0.11 | |
Operating CF/Net income |
0.13 | 0.04 | 0.10 | (0.23) | |
Capex/Depreciation |
(0.39) | (1.31) | (1.85) | (0.37) | |
Research and Development Expense of Revenue |
790.84% | 1,702.84% | 186.56% | 169.68% | |
Selling, General and Administrative Expense of Revenue |
416.48% | 790.91% | 122.56% | 137.72% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
102.24% | 189.77% | 42.10% | 57.86% | |
Graham Net Nets |
(0.29) | (1.15) | (0.89) | (0.74) | |
Graham Number |
37.14 | 137.30 | 146.58 | 125.59 | |
Earnings Yield |
(173.31%) | (147.65%) | (129.04%) | (144.08%) | |
Free Cash Flow Yield |
(19.04%) | (17.97%) | (10.56%) | (11.56%) | |
Revenue per Share |
0.11 | 0.07 | 0.46 | 0.43 | |
Operating CF per Share |
(1.05) | (0.78) | (1.14) | (0.64) | |
Capex per Share |
0.00 | (0.01) | (0.01) | 0.00 | |
Free Cash Flow per Share |
(1.06) | (0.79) | (1.15) | (0.64) | |
Cash per Share |
9.49 | 11.93 | 9.76 | 8.75 | |
Shareholders Equity per Share |
(2.74) | (25.11) | (25.40) | (18.75) | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
(2.74) | (25.11) | (25.40) | (18.75) | |
Free Cash Flow |
(9.06) | (5.87) | (12.61) | (7.43) | |
Working Capital |
79.33 | 81.63 | 104.38 | 100.39 | |
Capital Expenditures |
(0.02) | (0.06) | (0.12) | (0.02) | |
Net Current Asset Value |
(31.70) | (194.93) | (284.91) | (224.87) | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.02 | 0.11 | 0.02 | 0.00 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
7.38 | 1.37 | 3.82 | 3.78 | |
Average Payables |
0.41 | 0.52 | 0.60 | 0.71 | |
Average Assets |
71.02 | 73.60 | 117.77 | 109.15 | |
Average Common Equity |
(8.92) | (104.57) | (136.24) | (85.78) |
Columns are period end dates